Drug Profile
Research programme: Axl receptor tyrosine kinase inhibitors - Astex Pharmaceuticals
Alternative Names: Axl-9; SGI-AXL-277Latest Information Update: 19 Apr 2012
Price :
$50
*
At a glance
- Originator SuperGen
- Developer Astex Pharmaceuticals
- Class Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Haematological malignancies
Most Recent Events
- 15 Mar 2012 Discontinued for Haematological malignancies in USA (unspecified route)
- 23 May 2007 Pharmacodynamics data from a Preclinical trial in Cancer presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007)
- 01 Dec 2006 Early research in Cancer in USA (unspecified route)